Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer
详细信息 查看全文
- 作者：Manxiu Li1 ; Juan Zhang1 ; Tao Ouyang ; Jinfeng Li ; Tianfeng Wang ; Zhaoqing Fan ; Tie Fan ; Benyao Lin ; Yuntao Xie ; zlxyt2@bjmu.edu.cn" class="auth_mail" title="E-mail the corresponding author
- 关键词：TNBC ; triple-negative breast cancer ; HR ; homologous recombination ; PARP1 ; poly (ADP ribose) polymerase-1 ; ER ; Estrogen receptor ; PR ; progesterone receptor ; pCR ; pathologic complete response ; RT-PCR ; Reverse Transcription PCR ; LN ; Lymph nodes ; IDC ; invasive ductal carcinoma ; P ; positive ; N ; negative ; BIC ; The Breast Cancer Information Core ; CTF ; 5-fluorouracil ; pirarubicin ; and cyclophosphamide ; CTF/TP ; 5-fluorouracil ; pirarubicin ; and cyclophosphamide regimen followed by paclitaxel plus carbopla
- 刊名：Gene
- 出版年：2016
- 出版时间：10 June 2016
- 年：2016
- 卷：584
- 期：1
- 页码：26-30
- 全文大小：407 K
文摘
- •
We determine BRCA1 somatic mutations in a relatively large cohort of triple-negative breast cancers (TNBC).
- •
Approximately 3.9% of TNBC patients carried a BRCA1 deleterious somatic mutation.
- •
TNBC patients with a BRCA1 deleterious somatic mutation are likely to respond to neoadjuvant chemotherapy.